Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
Retrieved on:
Monday, October 3, 2022
Maintenance, ARV Super2, Forward-looking statement, GLOBE, NASDAQ, HIV-1, EDGAR, Subtypes of HIV, Dizziness, FDA, Allergy, SEDAR, Mission statement, MDR, ARV, Immune system, Breast milk, HIV, Infection, Power, Safety, Diarrhea, Immune reconstitution inflammatory syndrome, Program, Union, Patient, PK, Viral load, Vitamin, Rash, TSX, USP, Nausea, IV, Ibalizumab, Company, Pharmaceutical industry, Vaccine
The evolution of Trogarzo administration from intravenous infusion to intravenous push means less preparation and treatment time in clinics for patients and their health care providers, possibly allowing for more clinics to administer this treatment.
Key Points:
- The evolution of Trogarzo administration from intravenous infusion to intravenous push means less preparation and treatment time in clinics for patients and their health care providers, possibly allowing for more clinics to administer this treatment.
- We are proud of our long-term commitment to bring much needed non-oral innovations to help shift the treatment paradigm for heavily treatment-experienced people living with HIV.
- Results show that the safety and PK profile of Trogarzo administered via IV push are similar to that of IV infusion administration.
- Do not receive Trogarzo if you have had an allergic reaction to Trogarzo or any of the ingredients in Trogarzo.